Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 33.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,972 shares of the company's stock after selling 45,890 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of Denali Therapeutics worth $1,895,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in Denali Therapeutics in the third quarter valued at about $73,000. PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the last quarter. KBC Group NV boosted its stake in Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after purchasing an additional 2,731 shares in the last quarter. AlphaQuest LLC increased its stake in Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after purchasing an additional 4,449 shares in the last quarter. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after buying an additional 2,436 shares during the period. Institutional investors and hedge funds own 92.92% of the company's stock.

Remove Ads

Insider Transactions at Denali Therapeutics

In related news, insider Carole Ho sold 12,255 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 over the last ninety days. Insiders own 7.90% of the company's stock.

Denali Therapeutics Stock Up 11.8 %

Shares of NASDAQ DNLI traded up $1.45 during trading on Wednesday, hitting $13.74. The company had a trading volume of 3,629,147 shares, compared to its average volume of 1,053,691. Denali Therapeutics Inc. has a fifty-two week low of $12.05 and a fifty-two week high of $33.33. The stock has a fifty day simple moving average of $18.48 and a two-hundred day simple moving average of $22.91. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -4.98 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DNLI shares. HC Wainwright upped their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research report on Friday, February 28th. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target on the stock. Baird R W upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. Finally, Morgan Stanley assumed coverage on shares of Denali Therapeutics in a report on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.20.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.